Terms: = Endocrine gland cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck AND Treatment
10 results:
1. A multimodal radiomic machine learning approach to predict the lck expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract] [Full Text] [Related]
2. lck facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Dey G; Bharti R; Braley C; Alluri R; Esakov E; Crean-Tate K; McCrae K; Joehlin-Price A; Rose PG; Lathia J; Gong Z; Reizes O
J Ovarian Res; 2023 Jun; 16(1):122. PubMed ID: 37370140
[TBL] [Abstract] [Full Text] [Related]
3. Pretreatment with lck inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors.
Crean-Tate KK; Braley C; Dey G; Esakov E; Saygin C; Trestan A; Silver DJ; Turaga SM; Connor EV; DeBernardo R; Michener CM; Rose PG; Lathia J; Reizes O
J Ovarian Res; 2021 Apr; 14(1):55. PubMed ID: 33888137
[TBL] [Abstract] [Full Text] [Related]
4. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.
Creeden JF; Alganem K; Imami AS; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213062
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.
Ayhan A; Akilli H
Int J Gynaecol Obstet; 2021 Feb; 152(2):202-207. PubMed ID: 33020918
[TBL] [Abstract] [Full Text] [Related]
6. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
[TBL] [Abstract] [Full Text] [Related]
7. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract] [Full Text] [Related]
8. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.
Fuh KC; Shin JY; Kapp DS; Brooks RA; Ueda S; Urban RR; Chen LM; Chan JK
Gynecol Oncol; 2015 Mar; 136(3):491-7. PubMed ID: 25455734
[TBL] [Abstract] [Full Text] [Related]
9. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets.
Capurso G; Lattimore S; Crnogorac-Jurcevic T; Panzuto F; Milione M; Bhakta V; Campanini N; Swift SM; Bordi C; Delle Fave G; Lemoine NR
Endocr Relat Cancer; 2006 Jun; 13(2):541-58. PubMed ID: 16728581
[TBL] [Abstract] [Full Text] [Related]
10. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Gallo D; Giacomelli S; Ferlini C; Raspaglio G; Apollonio P; Prislei S; Riva A; Morazzoni P; Bombardelli E; Scambia G
Eur J Cancer; 2003 Nov; 39(16):2403-10. PubMed ID: 14556934
[TBL] [Abstract] [Full Text] [Related]
